Literature DB >> 7726793

Thyroid-associated ophthalmopathy: pathogenesis and clinical management.

P Perros1, P Kendall-Taylor.   

Abstract

The pathogenesis of thyroid-associated ophthalmopathy is autoimmune. The questions to which answers are eagerly awaited are the identification of the autoantigen(s) and the definition of the autoimmune processes (cellular or humoral) responsible. Cellular and humoral immune responses and modulation by cytokines, against orbital tissues have been described. A link between the thyroid and the orbit seems inevitable, possibly in the form of a cross-reactive antigen, and top of the list of candidate antigens is the TSH receptor. Optimal treatment of TAO necessitates careful assessment. Thoughtful planning and timing and choice of intervention with conventional therapies, can lead to satisfactory results in the majority of cases. In addition to treating the severe complications, such as optic neuropathy, corneal exposure and muscle misalignment, corrective surgery to reconstruct the appearance of the patient's eyes should be made available.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7726793     DOI: 10.1016/s0950-351x(95)80867-1

Source DB:  PubMed          Journal:  Baillieres Clin Endocrinol Metab        ISSN: 0950-351X


  8 in total

1.  T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy.

Authors:  A Pappa; J M Lawson; V Calder; P Fells; S Lightman
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

Review 2.  Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease.

Authors:  M Ludgate; G Baker
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

3.  Thyroid associated ophthalmopathy: evidence for CD4(+) gammadelta T cells; de novo differentiation of RFD7(+) macrophages, but not of RFD1(+) dendritic cells; and loss of gammadelta and alphabeta T cell receptor expression.

Authors:  A K Eckstein; B Quadbeck; S Tews; K Mann; C Krüger; C H Mohr; K-P Steuhl; J Esser; R K Gieseler
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

4.  The role of IL-15 and selenium in Graves ophthalmopathy.

Authors:  Se Jin Park; Jae Il Shin
Journal:  Nat Rev Endocrinol       Date:  2011-11-23       Impact factor: 43.330

5.  Value of thyroid stimulating antibody in the diagnosis of thyroid associated ophthalmopathy of euthyroid patients.

Authors:  K Kazuo; T Fujikado; G Ohmi; J Hosohata; Y Tano
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

Review 6.  Orbital Decompression for Thyroid Eye Disease.

Authors:  Tara L Braun; Mohin A Bhadkamkar; Kevin T Jubbal; Adam C Weber; Douglas P Marx
Journal:  Semin Plast Surg       Date:  2017-02       Impact factor: 2.314

7.  Thyroid transcription factor-1 in orbital adipose tissues: potential role in orbital thyrotropin receptor expression.

Authors:  Kalyan K Bhattacharyya; Michael J Coenen; Rebecca S Bahn
Journal:  Thyroid       Date:  2005-05       Impact factor: 6.568

Review 8.  Critical Appraisal on Orbital Decompression for Thyroid Eye Disease: A Systematic Review and Literature Search.

Authors:  Konstadinos G Boboridis; Jimmy Uddin; Dimitrios G Mikropoulos; Catey Bunce; George Mangouritsas; Irini C Voudouragkaki; Anastasios G P Konstas
Journal:  Adv Ther       Date:  2015-07-23       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.